Similar articles for PMID: 31182661

Year	Number of Results
2007	2
2009	1
2011	1
2012	1
2013	4
2014	3
2015	3
2016	18
2017	23
2018	22
2019	39
2020	45
2021	38
2022	19
2023	2

1

Best Practices for ¹⁸F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists.

Tade FI, Sajdak RA, Gabriel M, Wagner RH, Savir-Baruch B. Tade FI, et al. J Nucl Med Technol. 2019 Dec;47(4):282-287. doi: 10.2967/jnmt.119.227116. Epub 2019 Jun 10. J Nucl Med Technol. 2019. PMID: 31182661 Free article.

2

Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM. Odewole OA, et al. Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18. Eur J Nucl Med Mol Imaging. 2016. PMID: 27091135 Free PMC article.

3

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

4

Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.

Marcus C, Butler P, Bagrodia A, Cole S, Subramaniam RM. Marcus C, et al. AJR Am J Roentgenol. 2020 Aug;215(2):267-276. doi: 10.2214/AJR.19.22404. Epub 2020 Jun 17. AJR Am J Roentgenol. 2020. PMID: 32551903 Review.

5

Metastatic Male Breast Cancer With Increased Uptake on 18F-Fluciclovine PET/CT Scan.

Gill HS, Tade F, Greenwald DT, Yonover PM, Savir-Baruch B. Gill HS, et al. Clin Nucl Med. 2018 Jan;43(1):23-24. doi: 10.1097/RLU.0000000000001893. Clin Nucl Med. 2018. PMID: 29189374

6

Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.

Savir-Baruch B, Lovrec P, Solanki AA, Adams WH, Yonover PM, Gupta G, Schuster DM. Savir-Baruch B, et al. AJR Am J Roentgenol. 2019 Oct;213(4):851-858. doi: 10.2214/AJR.19.21153. Epub 2019 Jun 19. AJR Am J Roentgenol. 2019. PMID: 31216198

7

¹⁸F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard: A Systematic Review.

Seierstad T, Hole KH, Tulipan AJ, Strømme H, Lilleby W, Revheim ME, Hernes E. Seierstad T, et al. PET Clin. 2021 Apr;16(2):167-176. doi: 10.1016/j.cpet.2020.12.012. PET Clin. 2021. PMID: 33648662 Free article. Review.

8

Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.

Schreibmann E, Schuster DM, Rossi PJ, Shelton J, Cooper S, Jani AB. Schreibmann E, et al. Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):206-13. doi: 10.1016/j.ijrobp.2016.04.023. Epub 2016 Apr 30. Int J Radiat Oncol Biol Phys. 2016. PMID: 27511856 Free PMC article. Clinical Trial.

9

Detection of Additional Primary Neoplasms on ¹⁸F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer.

Parihar AS, Schmidt LR, Dehdashti F, Wahl RL. Parihar AS, et al. J Nucl Med. 2022 May;63(5):713-719. doi: 10.2967/jnumed.121.262647. Epub 2021 Aug 19. J Nucl Med. 2022. PMID: 34413144

10

Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for ¹⁸F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease.

Kim EH, Siegel BA, Teoh EJ, Andriole GL; LOCATE Study Group. Kim EH, et al. Urol Oncol. 2021 Jun;39(6):365.e9-365.e16. doi: 10.1016/j.urolonc.2020.10.017. Epub 2020 Nov 5. Urol Oncol. 2021. PMID: 33160848 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed